KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Assets (2017 - 2025)

Aquestive Therapeutics has reported Current Assets over the past 9 years, most recently at $149.3 million for Q4 2025.

  • Quarterly results put Current Assets at $149.3 million for Q4 2025, up 69.2% from a year ago — trailing twelve months through Dec 2025 was $149.3 million (up 69.2% YoY), and the annual figure for FY2025 was $149.3 million, up 69.2%.
  • Current Assets for Q4 2025 was $149.3 million at Aquestive Therapeutics, down from $151.7 million in the prior quarter.
  • Over the last five years, Current Assets for AQST hit a ceiling of $151.7 million in Q3 2025 and a floor of $38.1 million in Q3 2022.
  • Median Current Assets over the past 5 years was $48.7 million (2021), compared with a mean of $69.9 million.
  • Biggest five-year swings in Current Assets: dropped 24.14% in 2022 and later soared 161.41% in 2024.
  • Aquestive Therapeutics' Current Assets stood at $47.3 million in 2021, then dropped by 15.6% to $39.9 million in 2022, then rose by 2.7% to $41.0 million in 2023, then surged by 115.35% to $88.2 million in 2024, then soared by 69.2% to $149.3 million in 2025.
  • The last three reported values for Current Assets were $149.3 million (Q4 2025), $151.7 million (Q3 2025), and $81.7 million (Q2 2025) per Business Quant data.